|
XPR1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
2.81779999999898E-07 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
1.6333046026773E-11 |
| Stage1-vs-Stage2 |
4.815600E-02 |
| Stage1-vs-Stage3 |
6.789600E-01 |
| Stage1-vs-Stage4 |
4.885800E-01 |
| Stage2-vs-Stage3 |
4.524400E-02 |
| Stage2-vs-Stage4 |
3.140000E-02 |
| Stage3-vs-Stage4 |
7.478000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
2.16770000005528E-06 |
| Normal-vs-Asian |
2.56930032804803E-10 |
| Caucasian-vs-AfricanAmerican |
8.704200E-02 |
| Caucasian-vs-Asian |
6.779600E-01 |
| AfricanAmerican-vs-Asian |
9.843900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62436730732907E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.226200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
2.47024622979097E-13 |
| Normal-vs-Age(81-100Yrs) |
4.500400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.248000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.086400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.068600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.989800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.053000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.929000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.635000E-01 |
| Classical-VS-Follicular |
1.62436730732907E-12 |
| Classical-VS-Other |
3.685600E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
7.19380000013814E-09 |
| Tall-VS-Other |
3.317000E-01 |
| Tall-VS-Normal |
3.52995410679569E-12 |
| Follicular-VS-Other |
3.205800E-02 |
| Follicular-VS-Normal |
8.63850002641442E-09 |
| Other-VS-Normal |
1.389790E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
1.65223390524716E-12 |
| N0-vs-N1 |
4.332500E-02 |
|
|
